Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARK: Prolastin-C Dose Comparison in AATD
NCT01213043Phase 2Completed
- Sponsor
- Grifols
- Start
- Nov 2010
- Primary completion
- Jan 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alpha1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD) (2 arms), sponsored by Grifols. Primary endpoints: Treatment-Emergent Adverse Events at 22 weeks, Drug-Related Treatment-Emergent Adverse Events at 22 weeks and 2 more. Started Nov 2010; status: completed.
02
Drugs
alpha1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT01213043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01213043.